Strong Revenue Growth: STERIS reported a 9% increase in total revenue for Q1 2026, with constant currency organic revenue growth of 8%. This growth was driven by both volume increases and a price increase of 230 basis points. STERIS's Healthcare sector saw specific growth in capital equipment and service revenues, with a strong backlog of over $400 million.

Earnings Performance: Adjusted earnings per diluted share increased by 15% year-over-year to $2.34. Net income from continuing operations was reported at $231.2 million. This robust performance highlights the company's effective management of costs and operational efficiency, achieving an EBIT margin of 22.8%.

Raised Free Cash Flow Guidance: STERIS increased its free cash flow expectation for fiscal 2026 by $50 million to $820 million, supported by improved working capital management and strong earnings growth. This reflects the company¡¯s healthy cash generation capabilities in a strong start to the fiscal year.